Shielding the Stomach: Tegoprazan Matches Lansoprazole in Preventing NSAID-Induced Ulcers

Source

Source: Data derived from a Phase III, randomized, multicenter study evaluating the safety and efficacy of tegoprazan for the prevention of peptic ulcer in patients on continuous long-term NSAID treatment (NCT04840550).

A Phase III Randomized Double-Blind Trial Comparing P-CAB vs PPI for Long-Term NSAID Users

Phase III, N=392 24 Weeks Continuous Double-Blind Comparator

Primary Efficacy: Ulcer Prevention

Tegoprazan 25 mg successfully prevents NSAID-induced gastroduodenal ulcers over 24 weeks, proving statistically non-inferior to the established standard.

Tegoprazan

25 mg

NON-INFERIOR

p=0.0004

Lansoprazole

15 mg

Superior Heartburn Relief

At Week 12, the heartburn-free rate was significantly higher in patients taking tegoprazan compared to those on the established standard.

p=0.0421 at Week 12

Comparable Safety

Safety outcomes—including both general Adverse Drug Reactions (ADRs) and Serious Adverse Events (SAEs)—demonstrated no significant differences between treatment arms.

Equivalent Tolerability

Numbers to Know

392

Randomized Patients

Weeks Treatment

p=0.0421

Heartburn Benefit

Clinical Takeaway

Tegoprazan 25 mg offers an excellent, clinically effective alternative gastroprotective therapy. Physicians can confidently prescribe this novel P-CAB to prevent peptic ulcers in patients requiring long-term NSAID treatment, with the added benefit of improved heartburn control.

AbbreviationsQuick

ADR: adverse drug reaction; NSAID: nonsteroidal anti-inflammatory drug; SAE: serious adverse event.

Bibliography1

Kim SG, Kim TO, Jung SW, et al. A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs. Gut Liver. 2026 Jun 22. Epub ahead of print. PMID: 42325011. (DOI: 10.5009/gnl260057)

👀 View Mode